Drug trial results and the stock moves that follow

26 resultsPublic companies only
Met endpoint

RAP-219

Phase 2 n=253 Bipolar 1 Disorder

Rapport Therapeutics RAPP

Stock move (first trade) +8.11%
Missed endpoint

Firmonertinib

Phase 3 n=398 Metastatic Non-Small Cell Lung Cancer

ArriVent AVBP

24h stock move −48.74%
Met endpoint

VAX-31

Phase 3 n=4,049 Pneumococcal Disease

Vaxcyte PCVX

24h stock move +29.23%
Met endpoint

tabirafusp

Phase 3 n=675 Wet Age-related Macular Degeneration

Kodiak Sciences KOD

24h stock move +168.93%
Met endpoint

Barzolvolimab

Phase 3 n=963 Chronic Spontaneous Urticaria

Celldex CLDX

24h stock move −11.59%
Met endpoint

DT120

Phase 3 Generalized Anxiety Disorder

Definium Therapeutics DFTX

24h stock move +4.78%
Met endpoint

Mosliciguat

Phase 2 n=135 Pulmonary Hypertension

Roivant ROIV

24h stock move +18.75%
Missed endpoint

Envudeucitinib

Phase 2 n=408 SLE

Alumis ALMS

24h stock move −54.05%
Met endpoint

Avexitide

Phase 3 n=75 Post Bariatric Hypoglycemia

Amylyx Pharmaceuticals AMLX

24h stock move +66.59%
Met endpoint

NEO100

Phase 2 Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies NTHI

24h stock move −20.91%
Met endpoint

DT120

Phase 3 Generalized Anxiety Disorder

Definium Therapeutics DFTX

24h stock move +6.09%
Met endpoint

Divesiran

Phase 2 Polycythemia Vera

Silence Therapeutics SLN

24h stock move +30.88%
Missed endpoint

TNX-103

Phase 3 n=230 Pulmonary Hypertension

Tenax Therapeutics TENX

24h stock move −89.29%
Met endpoint

Pemvidutide

Phase 2 n=100 Alcohol Use Disorder (AUD)

Altimmune ALT

24h stock move +1.35%
Met endpoint

ML-007C

Phase 2 Schizophrenia

MapLight Therapeutics MPLT

24h stock move −73.66%
Missed endpoint

ML-004

Phase 2 n=168 Autism Spectrum Disorder

MapLight MPLT

24h stock move +3.37%
Met endpoint

ZYNLONTA

Phase 3 n=440 Relapsed Diffuse Large B-Cell Lymphoma

ADC Therapeutics ADCT

24h stock move −55.84%
Met endpoint

ublituximab

Phase 3 Relapsing Forms of Multiple Sclerosis

TG Therapeutics TGTX

24h stock move −0.97%
Met endpoint

Zumilokibart

Phase 2 Atopic Dermatitis

Apogee Therapeutics APGE

24h stock move −6.11%
Met endpoint

RGX-202

Phase 3 Duchenne Muscular Dystrophy

REGENXBIO RGNX

24h stock move −38.15%
Met endpoint

LUMRYZ

Phase 3 Idiopathic Hypersomnia

Alkermes plc. ALKS

24h stock move +7.13%
Met endpoint

Abdakibart

Phase 2 n=253 Hidradenitis Suppurativa

Avalo Therapeutics AVTX

24h stock move +33.83%
Met endpoint

VDPHL01

Phase 2/3 n=480 Androgenetic Alopecia

Veradermics MANE

24h stock move +41.51%
Met endpoint

ORKA-001

Phase 2 Plaque Psoriasis

Oruka Therapeutics ORKA

24h stock move +12.99%
Missed endpoint

ALTO-101

Phase 2 n=82 Schizophrenia

Alto Neuroscience ANRO

24h stock move −7.39%
Page 1 of 2

Daily roundups

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.